S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:ACHV

Achieve Life Sciences - ACHV Stock Forecast, Price & News

$2.58
-0.05 (-1.90%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.55
$2.65
50-Day Range
$2.02
$3.58
52-Week Range
$2.00
$8.61
Volume
20,675 shs
Average Volume
120,920 shs
Market Capitalization
$24.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Achieve Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
571.8% Upside
$17.33 Price Target
Short Interest
Bearish
5.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.14) to ($2.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

763rd out of 1,027 stocks

Diagnostic Substances Industry

9th out of 14 stocks

ACHV stock logo

About Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Stock News Headlines

Achieve Announces Close of Innovative, $175M HELOC Securitization
ACHV: 3Q:22 Results: Target Enrollments Reached
Achieve Life Sciences's Earnings Outlook
Achieve Welcomes Kingsley Forde, Director of Diversity and Inclusion
ACHV: Autumn Enrollment Completion for ORCA-3
Achieve Life Sciences Misses Q2 EPS by 27c
Achieve Life Sciences Inc - Stock Quote ACHV
See More Headlines
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Company Calendar

Last Earnings
11/09/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHV
CUSIP
68230A10
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.33
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+571.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-33,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.97 per share

Miscellaneous

Free Float
9,585,000
Market Cap
$24.97 million
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Dr. Richard A. B. Stewart (Age 63)
    Exec. Chairman
    Comp: $660k
  • Mr. John A. Bencich M.B.A. (Age 45)
    CEO & Director
    Comp: $767.25k
  • Dr. Cindy Jacobs M.D. (Age 64)
    Ph.D., Pres, Chief Medical Officer & Director
    Comp: $668.8k
  • Mr. Jerry Wan (Age 40)
    Principal Accounting Officer
  • Dr. Anthony Clarke (Age 66)
    Chief Scientific Officer
  • Ms. Jaime Xinos
    Exec. VP of Commercial













ACHV Stock - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings
or view top-rated stocks.

What is Achieve Life Sciences' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year price objectives for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $8.00 to $24.00. On average, they predict the company's share price to reach $17.33 in the next twelve months. This suggests a possible upside of 571.8% from the stock's current price.
View analysts price targets for ACHV
or view top-rated stocks among Wall Street analysts.

How have ACHV shares performed in 2022?

Achieve Life Sciences' stock was trading at $7.78 at the beginning of the year. Since then, ACHV stock has decreased by 66.8% and is now trading at $2.58.
View the best growth stocks for 2022 here
.

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 334,100 shares, an increase of 11.7% from the October 31st total of 299,200 shares. Based on an average daily volume of 60,400 shares, the short-interest ratio is currently 5.5 days. Approximately 5.4% of the company's stock are short sold.
View Achieve Life Sciences' Short Interest
.

When is Achieve Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our ACHV earnings forecast
.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($1.09) by $0.38. During the same quarter last year, the firm earned ($1.14) earnings per share.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Long Focus Capital Management LLC (3.18%), Perkins Capital Management Inc. (2.25%), Citadel Advisors LLC (0.36%), Royal Bank of Canada (0.35%), Group One Trading L.P. (0.00%) and Raymond James & Associates (0.18%).
View institutional ownership trends
.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $2.58.

How much money does Achieve Life Sciences make?

Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $24.97 million. The biopharmaceutical company earns $-33,150,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.

This page (NASDAQ:ACHV) was last updated on 12/8/2022 by MarketBeat.com Staff